Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | HCK | P08631 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.46 |
| ▸ | PRKDC | P78527 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL15019713 | 0.80 | FGFR2 (0.63) | LRRK2PIK3CDABL1EGFRHCK | |
| Ammonia Solution, Strong SCHEMBL1641642 | 0.77 | FGFR2 (0.48) | LRRK2PIK3CDABL1EGFRHCK | |
| SCHEMBL722260 | 0.76 | FGFR2 (0.54) | LRRK2PIK3CDABL1EGFRHCK | |
| SCHEMBL12680497 | 0.75 | NPC1 (0.56) | LRRK2NPC1CYP2A6AHRNR4A2 | |
| SCHEMBL1641747 | 0.72 | FGFR2 (0.67) | EGFRKDRFGFR2FLT3 | |
| SCHEMBL1640616 | 0.72 | BRAF (0.58) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL12488659 | 0.71 | ALDH1A1 (0.41) | KDRNPC1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2645009 | 0.71 | MAP3K11 (0.56) | LRRK2NPC1MAP3K11CYP3A4CYP2D6 | |
| SCHEMBL10187344 | 0.71 | LRRK2 (0.67) | LRRK2NPC1AHRMAP3K11CYP3A4 | |
| SCHEMBL2745043 | 0.71 | DHFR (0.59) | LRRK2NPC1MAP3K11CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436171-B2 | Amino substituted pyrazines as inhibitors or protein kinases | AKINION PHARMACEUTICALS AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | LRRK2 976/4885PIK3CD 1177/4885ABL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.